Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1293-1302

  Cornell, L D ^a   Schinstock, C A ^a   Gandhi, M J ^a   Kremers, W K ^a   Stegall, M D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alloantibody; antibody mediated (ABMR); chronic; crossmatch; fusion proteins; immunosuppressant; monoclonal antibodies

Indexed keywords

ECULIZUMAB; ANTIBODY; COMPLEMENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; BLOOD GROUP TYPING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; MALE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC DESENSITIZATION; BIOPSY; CHEMISTRY; CLINICAL TRIAL; COHORT ANALYSIS; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; KIDNEY TRANSPLANTATION; MIDDLE AGED; RENAL INSUFFICIENCY; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA EXCHANGE; RENAL INSUFFICIENCY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928089457     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13168     Document Type: Article

References (36)

1. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS, Calculated PRA:,. Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719-724.
2. Li H, Stegall MD, Dean PG, et al. Assessing the efficacy of kidney paired donation-performance of an integrated three-site program. Transplantation 2014.
3. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
4. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
5. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76-85.
6. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
7. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
8. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33: 1389-1401.
9. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995; 96: 1564-1572.
10. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760.
11. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526.
12. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
13. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
14. Gloor J, Cosio F, Lager DJ, Stegall MD,. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8: 1367-1373.
15. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006; 6: 1841-1847.
16. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
17. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800-805.
18. Wong W, Lee RA, Saidman SL, Smith RN, Zorn E,. Bortezomib in kidney transplant recipients with antibody mediated rejection: Three case reports. Clin Transpl 2009; 401-405.
19. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ,. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc 2009; 41: 3690-3692.
20. Everly JJ, Walsh RC, Alloway RR, Woodle ES,. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
21. Dunkelberger JR, Song WC,. Complement and its role in innate and adaptive immune responses. Cell research 2010; 20: 34-50.
22. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J,. The role of the anaphylatoxins in health and disease. Mol Immunol 2009; 46: 2753-2766.
23. Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Della Pelle P 2002; 73: 1431-1439.
24. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
25. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
26. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Neal Smith R 2012; 73: 1226-1232.
27. Hirohashi T, Chase CM, Della Pelle, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
28. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
29. Bian H, Harris PE, Mulder A, Reed EF,. Anti-HLA antibody ligation to HLA class I molecules expressed by endothelial cells stimulates tyrosine phosphorylation, inositol phosphate generation, and proliferation. Hum Immunol 1997; 53: 90-97.
30. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF,. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79: S19-S21.
31. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73: 1226-1232.
32. Hirohashi T, Chase CM, Della Pelle, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12: 313-321.
33. Lerut E, Kuypers DR, Verbeken E, et al. Acute rejection in non-compliant renal allograft recipients: A distinct morphology. Clin Transplant 2007; 21: 344-351.
34. El Ters, Grande M, Keddis JP, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13: 2334-2341.
35. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223-2230.
36. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410-417.